# APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a

Source: https://onco.cc/trials/nct04858334/  
OnCo record `nct04858334` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of olaparib in pancreatic cancer, run by National Cancer Institute (NCI), now recruiting.

## Summary

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation is a phase 2, randomised interventional study registered as NCT04858334 by National Cancer Institute (NCI), with a registry enrolment figure of 152 participants, started 2021-06-22 and due to reach its primary completion in 2027-10-31. Interventions recorded: Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Olaparib; Placebo Administration. Conditions listed: Pancreatic Acinar Cell Carcinoma; Pancreatic Adenosquamous Carcinoma; Pancreatic Squamous Cell Carcinoma; Resectable Pancreatic Acinar Cell Carcinoma; Resectable Pancreatic Adenocarcinoma; Resectable Pancreatic Adenosquamous Carcinoma; Resectable Pancreatic Carcinoma. Primary outcome: Improvement in relapse-free survival (RFS). Pancreatic eligibility wording from the registry: "* Patient must have a diagnosis of pancreatic cancer and have successfully undergone a curative intent surgical resection and must have no evidence of recurrent disease as determined by the investigator". Sites: Israel, Puerto Rico, United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT04858334
- Phase: 2
- Setting: APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- Sponsor: National Cancer Institute (NCI)
- Enrolled: 152

## Sources

- ClinicalTrials.gov NCT04858334: https://clinicaltrials.gov/study/NCT04858334

## Connected records

- cancers: [BRCA or PALB2-mutant pancreatic ductal adenocarcinoma](https://onco.cc/cancers/brca-palb2-pdac/), [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- technologies: [PARP inhibitors](https://onco.cc/technologies/parp-inhibitor/)
- drugs: [Olaparib](https://onco.cc/drugs/olaparib/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04858334.json